Anavex Life Sciences Corp. Stock price

Equities

AVXL

US0327973006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:50:55 2024-03-28 am EDT 5-day change 1st Jan Change
5.16 USD +1.98% Intraday chart for Anavex Life Sciences Corp. +0.98% -44.58%
Sales 2024 * - Sales 2025 * - Capitalization 415M
Net income 2024 * -46M Net income 2025 * -72M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-8.88 x
P/E ratio 2025 *
-5.82 x
Employees 40
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.86%
More Fundamentals * Assessed data
Dynamic Chart
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia CI
Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024
Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Anavex Life Sciences Initiates Phase 2 Trial of Schizophrenia Therapy MT
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia CI
Transcript : Anavex Life Sciences Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
Anavex Life Sciences Corp. Provides an Update on Rett Syndrome Program CI
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome CI
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
Anavex Life Sciences Shares Rise on European Approval of Marketing Application for Oral Blarcamesine in Alzheimer's MT
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease CI
Transcript : Anavex Life Sciences Corp., 2023 Earnings Call, Nov 27, 2023
Anavex Life Sciences Corp. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
More news
1 day+4.55%
1 week-1.17%
Current month-1.56%
1 month-5.07%
3 months-48.94%
6 months-25.70%
Current year-45.65%
More quotes
1 week
4.48
Extreme 4.48
5.11
1 month
4.48
Extreme 4.48
5.57
Current year
4.48
Extreme 4.48
6.95
1 year
4.48
Extreme 4.48
10.45
3 years
4.48
Extreme 4.48
31.50
5 years
2.20
Extreme 2.2
31.50
10 years
0.60
Extreme 0.6
31.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 13-07-04
Director of Finance/CFO 43 15-09-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 58 13-07-04
Founder 57 04-01-22
Chairman 60 21-05-24
More insiders
Date Price Change Volume
24-03-28 5.15 +1.78% 271 627
24-03-27 5.06 +4.55% 932,846
24-03-26 4.84 +6.37% 1,343,834
24-03-25 4.55 -2.36% 1,354,802
24-03-22 4.66 -8.81% 1,299,203

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.06 USD
Average target price
40 USD
Spread / Average Target
+690.51%
Consensus
  1. Stock
  2. Equities
  3. Stock Anavex Life Sciences Corp. - Nasdaq